HSF1 and acute myeloid leukemia: In addition, when we treated primary recipient mice twice with Tam (with a 10-day interval), no primary and secondary recipient mice developed AML (Fig. 1l, Supplementary Fig. 1e), indicating that Hsf1 ablation strongly impairs LSC self-renewal capacity.